💵 Femtech Investors in Southeast Asia

Access to capital in Southeast Asia (SEA) remains a critical factor in scaling femtech startups and women's health innovation. Startups in Singapore have had the most funding success across SEA to date.

Over 64% of femtech investors in SEA femtech startups are headquartered or have a regional office in SEA, noting more than ~44% of investors in SEA femtech are based in Singapore. US venture capital firms represent over 15% of femtech startup investors across the region.

Grant programmes in Singapore, sponsored by the universities, National Health Innovation Centre (NHIC), and government agency Enterprise Singapore, have played a critical role in funding and supporting the growth of local startups like EloCare and HiCura Medical, also supporting reach into neighbouring countries, like Singapore-headquartered FathomX, which has expanded into Indonesia, Malaysia and other SEA hospital systems - with sights set next on Japan and the USA.

Incubators and accelerators similarly are seeing femtech, especially reproductive health, as a primary investment opportunity. Examples include Y Combinator in the USA supporting twoplus Fertility, and Antler in Singapore investing in Zora Health.

Kindred Health Inc., the hybrid women’s healthcare company, is the only femtech company in the Philippines to have publicly-recorded funds raised. US-based Recharge Capital has selected womens’ health as a key thematic strategy, which translates to Rhea Fertility building a hybrid fertility ecosystem with companies like GenerationPrime, Madam Partum, Eluvo Health and more covering all aspects of the reproductive health journey. GenerationPrime in particular has significant USA backing from investment firms like Thiel Capital and Disney’s Shamrock Holdings. While headquartered in Singapore, GenerationPrime is operating in Thailand and recently launched in Malaysia.

Regional femtech industry M&A activity has been limited in SEA, with the only acquisition being a division of Ferne Health by PLans - Reproductive Health Assistant (since rebranded as Ovy Health in Q2 2025). There have not been any SEA femtech exits to date.

A unique funding model is through lifestyle and consumer companies. CPG-focused DSG and SEA’s retail giant Love, Bonito are investors in Moom Health as part of consumer engagement and wellness integration.

List excludes:

• Individual Angels and Family Office investors. Companies like Zora Health (SGP), Unprude (PHL), Ovy Health (IDN) among others have secured private and/or undisclosed investment.

• Startups operating, but not headquartered, in Asia.